Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer

University Health Network, Toronto

Status: Terminated

Conditions: Breast Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT01300871

10-0906-CE (Other Identifier)

Alopecia

Details and patient eligibility

About

This is a study to determine the prevalence and severity of alopecia (hair loss) experienced by postmenopausal breast cancer patients receiving endocrine therapy including Tamoxifen, Letrozole (Femara), Exemestane (Aromasin), or Anastrozole (Arimidex).

Enrollment: 100 estimated patients

Sex: Female

Ages: 40+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Postmenopausal women
• Diagnosed with hormone-receptor positive breast cancer
• Commenced adjuvant endocrine therapy ≥ 3 months ago, specifically Tamoxifen, Anastrozole, Exemestane, and/or Letrozole
• Good command of the English language
• Under the care of a medical oncologist at Princess Margaret Hospital

Exclusion criteria

• Previously received chemotherapy
• Recurrent and/or metastatic disease
• History of endocrine, dermatology, or immune system disorders known to alter hair growth (ie. Hypothyroidism and iron deficiency)

Trial design

100 participants in 1 patient group

Postmenopausal Women on Endocrine Therapy

Description:

Postmenopausal women with Breast Cancer that undergo Endocrine Therapy.